உயிரணு, திசு, மரபணு சிகிச்சைக்கு அரசாங்க நிதியுதவியைப் பயன்படுத்தலாம்

Patients here who require certain costly cell, tissue and gene therapy products (CTGTP) will now be eligible for subsidies, starting with one product for blood cancers. This opens the door for a new age of treatments for patients, harnessing cells as living drugs to treat or reverse various health conditions The subsidies began on Aug 1, according to the Ministry of Health’s (MOH), which noted the availability of such treatments at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the treatments usually prescribed by the doctors. Made from human or animal cells or tissues, or man-made genetic material, cell, tissue, and gene therapy products can be used to diagnose, treat, or prevent a variety of conditions. Several new cell therapy products have been approved by the United States Food and Drug Administration (FDA) in recent years, with more in the works. CAR T-cell therapy, for example, allows cancer patients to recover more quickly without the need for aggressive chemotherapy, and achieve longer-lasting remissions. Singapore sees about 100 patients each year who require cell and gene therapy treatments, which are usually offered to those who have not responded well to conventional treatments for conditions such as aggressive leukaemia and lymphoma. Singapore citizens are now eligible to get up to 75 per cent of the cost of their treatment subsidised, capped at $150,000, while permanent residents can get up to 22.5 per cent subsidies, capped at $45,000.